title: Anterior ischemic optic neuropathy.
authors.forename: Morteza
authors.initials: M
authors.lastname: Entezari
authors.forename: Alireza
authors.initials: A
authors.lastname: Ramezani
authors.forename: Mohammad
authors.initials: M
authors.lastname: Pakravan
authors.forename: Ali
authors.initials: A
authors.lastname: Mahmoodi
authors.forename: Hossein
authors.initials: H
authors.lastname: Hassanpour
authors.forename: Mehdi
authors.initials: M
authors.lastname: Yaseri
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide